Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorUniversity of Pavia
About this trial
This randomized controlled clinical trial aims to evaluate the effectiveness of adjunctive coenzyme Q10 and probiotic supplementation (Limosilactobacillus reuteri Prodentis®) in improving periodontal health in pregnant women undergoing non-surgical periodontal therapy. Forty participants will be randomly assigned to two groups: the test group will receive professional oral hygiene every three months along with a coenzyme Q10-based toothpaste and daily probiotic supplementation; the control group will follow the same protocol without probiotics. The primary outcome is the reduction of the Plaque Index (PI), while secondary outcomes include Bleeding on Probing (BoP), Probing Pocket Depth (PPD), Clinical Attachment Level (CAL), gingival inflammation (MGI, PMGI), plaque distribution (PCR%, API), and gingival recession (R). The study duration is 6 months. The goal is to assess whether this combined therapy can promote a balanced oral microbiota and enhance periodontal health during pregnancy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Pregnant women between the 4th and 8th month of gestation
Age ≥ 18 years
Able to understand and communicate in Italian and/or English
Willing to provide written informed consent
Disqualifiers
Presence of cardiac pacemakers
Diagnosed psychological, neurological, or psychiatric disorders
Ongoing oncological therapy
Use of bisphosphonates within the last 12 months
Trial design
Design model
Parallel
Treatments tested in this trial
Limosilactobacillus reuteri Prodentis®
Dietary supplementDaily administration of Limosilactobacillus reuteri Prodentis® (1 oral tablet per day, taken after brushing in the evening), as an adjunct to non-surgical periodontal therapy and standard home care. Administered for 6 months only in the experimental arm.
Coenzyme Q10 Toothpaste
Other interventionTwice-daily use of a commercially available toothpaste containing coenzyme Q10, used as part of a home oral hygiene regimen for 6 months. All participants in both study arms will use the same toothpaste, with or without adjunctive probiotic supplementation.
Treatment groups
40 Participants
are divided into 2 treatment groupsGroup A: Coenzyme Q10 Plus ProbioticsExperimental treatment 2 interventions
Group B: Coenzyme Q10 OnlyActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Change in Dental Plaque Measured by the Plaque Index Score
The Plaque Index (PI) Score will be recorded at four timepoints (baseline, 1 month, 3 months, and 6 months) to assess the amount of dental plaque accumulation. The primary endpoint is the change in PI from baseline (T0) to 6 months (T3), comparing the intervention group (coenzyme Q10 + probiotics) to the control group (coenzyme Q10 only). The index is measured by visually scoring the plaque on tooth surfaces using standardized criteria. The Plaque Index score ranges from 0 (no plaque) to 3 (abundant plaque), with higher scores indicating a worse outcome.
Time frame
Baseline (T0), 1 Month (T1), 3 Months (T2), and 6 Months (T3)Secondary outcomes
1
Change in Gingival Bleeding Measured by the Bleeding on Probing (BoP) Index
The BoP index will be recorded to evaluate gingival bleeding. Comparison will be made between the test group (coenzyme Q10 + probiotics) and the control group (Q10 only) across all study timepoints, from baseline to 6 months. The BoP index is expressed as the percentage of bleeding sites out of the total number of sites examined (range: 0% to 100%), with higher percentages indicating a worse outcome.
Time frame
Baseline (T0), 1 Month (T1), 3 Months (T2), and 6 Months (T3)2
Change in Periodontal Pocket Depth Measured by the Probing Pocket Depth (PPD)
PPD will be recorded in millimeters to assess periodontal pocket depth. Values will be compared between groups across timepoints to evaluate treatment efficacy. PPD values range from 1 mm (healthy sulcus) to over 7 mm (advanced periodontal disease); higher values indicate a worse outcome.
Time frame
Baseline (T0), 1 Month (T1), 3 Months (T2), and 6 Months (T3)3
Change in Clinical Attachment Level Measured by CAL
CAL will be measured to assess periodontal tissue support. The difference in attachment level from baseline to 6 months will be analyzed between study groups. CAL is measured in millimeters, typically ranging from 0 mm (no attachment loss) to over 10 mm in severe cases; higher values indicate a worse outcome.
Time frame
Baseline (T0), 1 Month (T1), 3 Months (T2), and 6 Months (T3)4
Change in Gingival Inflammation Measured by the Modified Gingival Index (MGI)
The MGI will be used to evaluate gingival inflammation. Score changes from baseline to 6 months will be analyzed between the intervention and control groups. The MGI ranges from 0 (normal gingiva) to 4 (severe inflammation), with higher scores indicating a worse outcome.
Time frame
Baseline (T0), 1 Month (T1), 3 Months (T2), and 6 Months (T3)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov